Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Buys Stake in Sangamo, Will Co-Develop, Sell ZFP Research Reagents

NEW YORK (GenomeWeb News) — Sigma-Aldrich has made a $7.8 million equity investment in Sangamo BioSciences as part of the companies’ plan to co-develop and market zinc finger-based research reagents, the firms said yesterday.
 
The companies will use Sangamo’s ZFP technology to develop the reagents for a variety of cell analysis applications including cell lines with enhanced protein production performance, panels of knock-out cell lines for drug discovery, and stem cell and transgenic animal models.
 
Under terms of the license, Sigma will make an initial payment to Sangamo of $13.5 million, which consists of an upfront license payment and the purchase of 1 million shares of Sangamo common stock at $7.75 per share.
 
Sigma will also pay Sangamo additional fees and minimum annual payments, along with up to $22 million in development and commercial milestone payments. Sigma will also pay the company royalties based on product sales.
 
Sigma has the right to sublicense the technology for research applications. If it takes that sublicense it would provide Sangamo with 50 percent of revenues from the sublicense in the first two years and 25 percent of revenues thereafter.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.